참고문헌
- Agus DB, Akita RW, Fox WD, et al (2002). Targeting ligandactivated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell, 2, 127-37. https://doi.org/10.1016/S1535-6108(02)00097-1
- Al-Hajj M, Wicha MS, Benito-Hernandez A, et al (2003). Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA, 100, 3983-8. https://doi.org/10.1073/pnas.0530291100
- Amiri-Kordestani L, Blumenthal GM, Xu QC, et al (2014). FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res, 20, 4436-41. https://doi.org/10.1158/1078-0432.CCR-14-0012
- Anderson NG, Ahmad T, Chan K, et al (2001). ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression. Int J Cancer, 94, 774-82. https://doi.org/10.1002/ijc.1557
- Baselga J (2001). Phase I and II clinical trials of trastuzumab. Ann Oncol, 12, 49-55.
- Basu A (2008). Molecular targets of breast cancer: AKTing in concert. Breast Cancer: Basic Clin Res, 2, 11-6.
- Bouchalova K, Cizkova M, Cwiertka K, et al (2009). Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomedical papers of the Medical Faculty of the University Palacky. Olomouc, Czechoslovakia, 153, 13-7. https://doi.org/10.5507/bp.2009.002
- Brand TM, Iida M, Li CR, et al (2011). The nuclear epidermal growth factor receptor signaling network and its role in cancer. Discovery Medicine, 66, 419-32.
- Brennan M, Lim B (2015). The actual role of receptors as cancer markers, biochemical and clinical aspects: receptors in breast cancer. Adv Exp Med Biol, 867, 327-37. https://doi.org/10.1007/978-94-017-7215-0_20
- Burgess AW, Henis YI, Hynes NE, et al (2014). EGF receptor family: twisting targets for improved cancer therapies. Growth Factors, 32, 74-81. https://doi.org/10.3109/08977194.2014.896355
- Canonici A, Gijsen M, Mullooly M, et al (2013). Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer. Oncotarget, 4, 1592-605. https://doi.org/10.18632/oncotarget.1148
- Carpenter G, Cohen S (1979). Epidermal growth factor. Annu Rev Biochem, 48, 193-216. https://doi.org/10.1146/annurev.bi.48.070179.001205
- Cho HS, Mason K, Ramyar KX, et al (2003). Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature, 421, 756-60. https://doi.org/10.1038/nature01392
- Dhomen NS, Mariadason J, Tebbutt N, et al (2012). Therapeutic targeting of the epidermal growth factor receptor in human cancer. Crit Rev Oncog, 17, 31-50. https://doi.org/10.1615/CritRevOncog.v17.i1.40
- Dick JE (2003). Breast cancer stem cells revealed. Proc Natl Acad Sci USA, 100, 3547-9. https://doi.org/10.1073/pnas.0830967100
- Dimitrakopoulos FI, Kottorou A, Antonacopoulou AG, et al (2015). Early-stage breast cancer in the elderly: confronting an old clinical problem. J Breast Cancer, 18, 207-17. https://doi.org/10.4048/jbc.2015.18.3.207
- Dontu G (2008). Breast cancer stem cell markers - the rocky road to clinical applications. Breast cancer research : BCR, 10, 110. https://doi.org/10.1186/bcr2130
- Dragu DL, Necula LG, Bleotu C, et al (2015). Therapies targeting cancer stem cells: Current trends and future challenges. World J Stem Cells, 7, 1185-201.
- Ennis BW, Lippman ME, Dickson RB (1991). The EGF receptor system as a target for antitumor therapy. Cancer Invest, 9, 553-62. https://doi.org/10.3109/07357909109018953
- Ettinger DS (2006). Clinical implications of EGFR expression in the development and progression of solid tumors: focus on non-small cell lung cancer. Oncologist, 11, 358-73. https://doi.org/10.1634/theoncologist.11-4-358
- Fan Z, Baselga J, Masui H, et al (1993). Antitumor effect of antiepidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res, 53, 4637-42.
- Foy KC, Wygle RM, Miller MJ, et al (2013). Peptide vaccines and peptidomimetics of EGFR (HER-1) ligand binding domain inhibit cancer cell growth in vitro and in vivo. J Immunol, 191, 217-27. https://doi.org/10.4049/jimmunol.1300231
- Gancberg D, Jarvinen T, di Leo A, et al (2002). Evaluation of HER-2/NEU protein expression in breast cancer by immunohistochemistry: an interlaboratory study assessing the reproducibility of HER-2/NEU testing. Breast Cancer Res Treat, 74, 113-20. https://doi.org/10.1023/A:1016146130767
- Geyer CE, Forster J, Lindquist D, et al (2006). Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med, 355, 2733-43. https://doi.org/10.1056/NEJMoa064320
- Ginestier C, Hur MH, Charafe-Jauffret E, et al (2007). ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell, 1, 555-67. https://doi.org/10.1016/j.stem.2007.08.014
- Gingras AC, Kennedy SG, O'Leary MA, et al (1998). 4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) signaling pathway. Genes Dev, 12, 502-13. https://doi.org/10.1101/gad.12.4.502
- Harris RC, Chung E, Coffey RJ (2003). EGF receptor ligands. Exp Cell Res, 284, 2-13. https://doi.org/10.1016/S0014-4827(02)00105-2
- Herbst RS, Bunn PA, Jr. (2003). Targeting the epidermal growth factor receptor in non-small cell lung cancer. Clin Cancer Res, 9, 5813-24.
- Huang L, Fu L (2015). Mechanisms of resistance to EGFR tyrosine kinase inhibitors. Acta Pharm Sin B, 5, 390-401. https://doi.org/10.1016/j.apsb.2015.07.001
- Iorio MV, Ferracin M, Liu CG, et al (2005). MicroRNA gene expression deregulation in human breast cancer. Cancer Res, 65, 7065-70. https://doi.org/10.1158/0008-5472.CAN-05-1783
- Iqbal N, Iqbal N (2014). Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications. Mol Biol Int, 2014, 852748.
- Kamath S, Buolamwini JK (2006). Targeting EGFR and HER-2 receptor tyrosine kinases for cancer drug discovery and development. Medicinal Res Reviews, 26, 569-94. https://doi.org/10.1002/med.20070
- Kanematsu T, Yano S, Uehara H, et al (2003). Phosphorylation, but not overexpression, of epidermal growth factor receptor is associated with poor prognosis of non-small cell lung cancer patients. Oncol Res, 13, 289-98. https://doi.org/10.3727/096504003108748348
- Knowlden JM, Hutcheson IR, Jones HE, et al (2003). Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology, 144, 1032-44. https://doi.org/10.1210/en.2002-220620
- Kondapaka SB, Fridman R, Reddy KB (1997). Epidermal growth factor and amphiregulin up-regulate matrix metalloproteinase-9 (MMP-9) in human breast cancer cells. Int J Cancer, 70, 722-6. https://doi.org/10.1002/(SICI)1097-0215(19970317)70:6<722::AID-IJC15>3.0.CO;2-B
- Korkaya H, Paulson A, Iovino F, et al (2008). HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene, 27, 6120-30. https://doi.org/10.1038/onc.2008.207
- Kute T, Lack CM, Willingham M, et al (2004). Development of Herceptin resistance in breast cancer cells. Cytometry A, 57, 86-93.
- Lau YK, Du X, Rayannavar V, et al (2014). Metformin and erlotinib synergize to inhibit basal breast cancer. Oncotarget, 5, 10503-17. https://doi.org/10.18632/oncotarget.2391
- Li X, Lewis MT, Huang J, et al (2008). Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst, 100, 672-9. https://doi.org/10.1093/jnci/djn123
- Liu Y, Chen C, Qian P, et al (2015). Gd-metallofullerenol nanomaterial as non-toxic breast cancer stem cell-specific inhibitor. Nat Commun, 6, 5988 https://doi.org/10.1038/ncomms6988
- Lyon, France (2013). International Agency for Research on Cancer.
- Madrid MA, Lo RW (2004). Chromogenic in situ hybridization (CISH): a novel alternative in screening archival breast cancer tissue samples for HER-2/neu status. Breast Cancer Res, 6, 593-600. https://doi.org/10.1186/bcr915
- Marquez A, Wu R, Zhao J, et al (2004). Evaluation of epidermal growth factor receptor (EGFR) by chromogenic in situ hybridization (CISH) and immunohistochemistry (IHC) in archival gliomas using bright-field microscopy. Diagnostic Molec Path, 13, 1-8. https://doi.org/10.1097/00019606-200403000-00001
- Martinelli E, De Palma R, Orditura M, et al (2009). Antiepidermal growth factor receptor monoclonal antibodies in cancer therapy. Clin Exp Immunol, 158, 1-9.
- Mayo LD, Donner DB (2001). A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci USA, 98, 11598-603. https://doi.org/10.1073/pnas.181181198
- Menard S, Pupa SM, Campiglio M, et al (2003). Biologic and therapeutic role of HER2 in cancer. Oncogene, 22, 6570-8. https://doi.org/10.1038/sj.onc.1206779
- Mendelsohn J (1997). Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clin Cancer Res, 3, 2703-7.
- Mendelsohn J (2000). Blockade of receptors for growth factors:an anticancer therapy--the fourth annual joseph H burchenal american association of cancer research clinical research award lecture. Clin Cancer Res, 6, 747-53.
- Mendez MJ, Green LL, Corvalan JR, et al (1997). Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice. Nature Genetics, 15, 146-56. https://doi.org/10.1038/ng0297-146
- Miki Y, Swensen J, Shattuck-Eidens D, et al (1994). A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science, 266, 66-71. https://doi.org/10.1126/science.7545954
- Morrison BJ, Schmidt CW, Lakhani SR, et al (2008). Breast cancer stem cells: implications for therapy of breast cancer. Breast Cancer Res, 10, 210. https://doi.org/10.1186/bcr2111
- Nahta R, Hung MC, Esteva FJ (2004). The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res, 64, 2343-6. https://doi.org/10.1158/0008-5472.CAN-03-3856
- Nicholson RI, Hutcheson IR, Harper ME, et al (2002). Modulation of epidermal growth factor receptor in endocrine-resistant, estrogen-receptor-positive breast cancer. Ann N Y Acad Sci, 963, 104-15.
- Nicholson RI, Hutcheson IR, Knowlden JM, et al (2004). Nonendocrine pathways and endocrine resistance:observations with antiestrogens and signal transduction inhibitors in combination. Clin Cancer Res, 10, 346-54. https://doi.org/10.1158/1078-0432.CCR-031206
- Normanno N, De Luca A, Bianco C, et al (2006). Epidermal growth factor receptor (EGFR) signaling in cancer. Gene, 366, 2-16. https://doi.org/10.1016/j.gene.2005.10.018
- O'Sullivan CC, Bradbury I, Campbell C, et al (2015). Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer and Tumors = 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials. J Clin Oncol, 33, 2600-8. https://doi.org/10.1200/JCO.2015.60.8620
- Park CY, Tseng D, Weissman IL (2009). Cancer stem celldirected therapies: recent data from the laboratory and clinic. Mol Ther, 17, 219-30. https://doi.org/10.1038/mt.2008.254
- Prenzel N, Fischer OM, Streit S, et al (2001). The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr Relat Cancer, 8, 11-31. https://doi.org/10.1677/erc.0.0080011
- Rhodes A, Jasani B, Anderson E, et al (2002). Evaluation of HER-2/neu immunohistochemical assay sensitivity and scoring on formalin-fixed and paraffin-processed cell lines and breast tumors: a comparative study involving results from laboratories in 21 countries. Am J Clin Pathol, 118, 408-17. https://doi.org/10.1309/97WN-W6UX-XJWT-02H2
- Ring A, Wheatley D, Hatcher H, et al (2014). Phase I study to assess the combination of afatinib with trastuzumab in patients with advanced or metastatic HER2-positive breast cancer. Clin Cancer Res, 21, 2737-44
- Ruddon RW 2007. Cancer Biology, Oxford, Oxford University Press Inc.
- Saura C, Garcia-Saenz JA, Xu B, et al (2014). Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol, 32, 3626-33. https://doi.org/10.1200/JCO.2014.56.3809
- Schramm A, De Gregorio N, Widschwendter P, et al (2015). Targeted therapies in HER2-positive breast cancer - a systematic review. Breast Care, 10, 173-8. https://doi.org/10.1159/000431029
- Schulz DM, Bollner C, Thomas G, et al (2009). Identification of differentially expressed proteins in triple-negative breast carcinomas using DIGE and mass spectrometry. J Proteome Res, 8, 3430-8. https://doi.org/10.1021/pr900071h
- Sergina NV, Rausch M, Wang D, et al (2007). Escape from HER-family tyrosine kinase inhibitor therapy by the kinaseinactive HER3. Nature, 445, 437-41. https://doi.org/10.1038/nature05474
- Shiovitz S, Korde LA (2015). Genetics of breast cancer: a topic in evolution. Ann Oncol, 26, 1291-9.
- Slamon DJ, Clark GM, Wong SG, et al (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science, 235, 177-82. https://doi.org/10.1126/science.3798106
- Slamon DJ, Godolphin W, Jones LA, et al (1989). Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science, 244, 707-12. https://doi.org/10.1126/science.2470152
- Tai W, Mahato R, Cheng K (2010). The role of HER2 in cancer therapy and targeted drug delivery. J Control Release, 146, 264-75. https://doi.org/10.1016/j.jconrel.2010.04.009
- Twelves CJ, Stebbing J (2012). Being there for women with metastatic breast cancer. a pan-European patient survey. Ann Oncol, 23, 132-.
- Valdehita A, Carmena MaJ, Bajo AM, et al (2012). RNA interference-directed silencing of VPAC1 receptor inhibits VIP effects on both EGFR and HER2 transactivation and VEGF secretion in human breast cancer cells. Molec Cellular Endocrinol, 348, 241-6. https://doi.org/10.1016/j.mce.2011.08.031
- Vandevijver MJ, Peterse JL, Mooi WJ, et al (1988). Neu-protein overexpression in breast-cancer - association with comedotype ductal carcinoma insitu and limited prognostic value in stage-II breast-cancer. N Engl J Med, 319, 1239-45. https://doi.org/10.1056/NEJM198811103191902
- Verma S, Miles D, Gianni L, et al (2012). Trastuzumab emtansine for HER2-positive advanced breast cancer. The New England journal of medicine, 367, 1783-91. https://doi.org/10.1056/NEJMoa1209124
- Welslau M, Diéras V, Sohn J-H, et al (2014). Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer. Cancer, 120, 642-51. https://doi.org/10.1002/cncr.28465
- Zaha DC (2014). Significance of immunohistochemistry in breast cancer. World J Clin Oncol, 5, 382-92. https://doi.org/10.5306/wjco.v5.i3.382
피인용 문헌
- ZNF516 suppresses EGFR by targeting the CtBP/LSD1/CoREST complex to chromatin vol.8, pp.1, 2017, https://doi.org/10.1038/s41467-017-00702-5
- Imbalance of the reciprocally inhibitory loop between the ubiquitin-specific protease USP43 and EGFR/PI3K/AKT drives breast carcinogenesis vol.28, pp.9, 2018, https://doi.org/10.1038/s41422-018-0079-6
- Epidermal growth factor receptor-mediated regulation of matrix metalloproteinase-2 and matrix metalloproteinase-9 in MCF-7 breast cancer cells pp.1573-4919, 2018, https://doi.org/10.1007/s11010-018-3417-6
- Monoclonal antibody-based therapeutics, targeting the epidermal growth factor receptor family: from herceptin to Pan HER vol.70, pp.7, 2018, https://doi.org/10.1111/jphp.12911
- Immunomodulatory Effects of Flavonoids: Possible Induction of T CD4+ Regulatory Cells Through Suppression of mTOR Pathway Signaling Activity vol.10, pp.1664-3224, 2019, https://doi.org/10.3389/fimmu.2019.00051